2024 SABCS会议预告｜12月13日有哪些精彩看点？

地点和时间：Hemisfair Ballroom 3，12月13日 7:00 – 8:30 am

主持人：Yara Abdou, University of North Carolina School of Medicine

PS10-01: Racial differences in the prevalence of biomarker alterations, treatment patterns, and clinical outcomes in hormone receptor–positive, human epidermal growth factor receptor 2–negative metastatic breast cancer: A national cohort study.

Pegah Farrokhi, University of Minnesota, Minneapolis, Minnesota

PS10-02: Pre-diagnosis Physical Activity and Racial Disparities in Breast Cancer Survival Outcomes: a Multiethnic Cohort Study.

Yijia Sun, University of Chicago, Chicago, Illinois

PS10-03: Socioeconomic disparities in long-term heart failure risk of trastuzumab with or without anthracyclines in early-stage breast cancer: A SEER-Medicare Database Analysis.

Karissa Britten, University of California Los Angeles David Geffen School of Medicine, Los Angeles, California

PS10-04: Identifying Risk Factors for High Allostatic Load in a Racially/Ethnically Diverse Cohort of Breast Cancer Patients.

Anna Vaynrub, Columbia University Vagelos College of Physicians and Surgeons, New York, New York

PS10-05: Door-to-door Breast Cancer Screening in 22,278 populaces from Feb. 2020-April 2024: Breast Cancer Hub's Trendsetting Grassroots Sustainable Solutions, overcoming the Disparity, & Challenges in the Rural Remote Villages in Poverty, of Assam, India.

Lopamudra Das Roy, Breast Cancer Hub, Concord, North Carolina

PS10-06: Access to Innovative Medicines for Advanced Breast Cancer as a Catalyst for Health Systems Strengthening in Low- and Middle-Income Countries.

Fatima Cardoso, Champalimaud Clinical Center, Lisbon, Portugal

PS10-07: The Molecular Subtypes of Breast Cancer: A Single Institution Experience after a Decade of the Syrian War.

Ayla Kouli, Damascus University, Damascus, Syria

PS10-08: Appalachian Mobile Mammogram Program Achieves Unprecedented Outcomes by Repeatedly Reaching Underserved Women.

John L. Bell, University of Tennessee Medical Center, Knoxville, Tennessee

PS10-09: Occupational Pesticide Exposure and Poor Prognosis Breast Cancer in Brazilian Women: Epidemiological Insights and Molecular Mechanisms.

Carolina Panis, Universidade Estadual do Oeste do Paraná, Francisco Beltrão, Brazil

• 7:30-7:45 Discussant (PS10-01, PS10-02, PS10-03, PS10-04)

弥合差距：解决乳腺癌结果中的种族差异

Bridging the Gap: Addressing Racial Disparities in Breast Cancer Outcomes

Dame’ Idossa, University of Minnesota Medical School, Minneapolis, Minnesota

• 7:45-8:00 Panel Q&A

• 8:00-8:15 Discussant (PS10-05, PS10-06, PS10-07, PS10-08, PS10-09)

促进全球卫生公平：解决资源匮乏环境中的差异

Advancing Global Health Equity: Addressing Disparities in Low-Resource Settings

Speaker to be announced

• 8:15-8:30 Panel Q&A

地点和时间：Hemisfair Ballroom 1-2，12月13日 7:00 – 8:30 am

主持人：David Mankoff, Perelman School of Medicine University of Pennsylvania

PS11-01: [18F]Fluoroestradiol (FES)-PET as a predictive measure for endocrine therapy in patients with newly diagnosed metastatic breast cancer: Results from EAI142.

Hannah Linden, Fred Hutchinson Cancer Center, Seattle, Washington

PS11-02: [18F]fluoroestradiol (FES) PET/CT to guide 2nd line treatment decision in patients with ER-positive HER2-negative advanced breast cancer (ABC) progressing on 1st line aromatase inhibitor and CDK4/6 inhibitor: early results of the ESTROTIMP trial.

Francois-Clement Bidard, Institut Curie, Paris, France

PS11-03: Comparative analysis of [18F]FES- and [18F]FDG-PET in patients with metastatic ER+  lobular breast cancer.

Jasmine Moustaquim, Antoni van Leeuwenhoekziekenhuis, Amsterdam, Netherlands

PS11-05: Novel 4D radiomics applied to dynamic FES PET images to improve prediction of ER-positive breast cancer outcomes for ER-targeted therapy.

Carla Zeballos Torrez, Penn Medicine University of Pennsylvania. Philadelphia, Pennsylvania

PS11-06: Leveraging AI to Predict Recurrence-Free Survival in Breast Cancer Patients through Image-Based assessment of Tumor Characteristics.

Poornima Saha, NorthShore University HealthSystem, Glenview, Illinois

PS11-07: Predicting the response of locally advanced breast cancer to neoadjuvant therapy using MRI-based mathematical modeling of the I-SPY 2 dataset.

Reshmi Patel, University of Texas at Austin Center for Computational Oncology, Austin, Texas

PS11-08: MRI提高了用于乳腺癌诊断和预后的多模态人工智能系统的效能

MRI improves multi-modal AI system for breast cancer diagnosis and prognosis.

Yanqi Xu 中国药科大学

PS11-09: Improving risk estimation for women with dense breasts.

Shu (Joy) Jiang, Washington University School of Medicine, St. Louis, Missouri

• 7:30-7:45 Discussant (PS11-01, PS11-02, PS11-03, PS11-05)

分子影像学评估ER+乳腺癌

Molecular Imaging to Assess ER+ Breast Cancer

Laura Kenney, Imperial College London, London, United Kingdom

• 7:45-8:00 Panel Q&A

• 8:00-8:15 Discussant (PS11-06, PS11-07, PS11-08, PS11-09)

AI和影像指导乳腺治疗

AI and Imaging to Guide Breast Treatment

Aimilia Gastounioti, Washington University School of Medicine, St. Louis, Missouri

• 8:15-8:30 Panel Q&A

地点和时间：  Room 221ABC，12月13日 7:00 – 8:30 am 

主持人：Lajos Pusztai, Yale School of Medicine, New Haven, Connecticut

PS12-01: Olaparib-induced early dynamics of tumor immune microenvironment in triple-negative or ER-low breast cancer: insights from a window of opportunity MEDIOLA trial of olaparib and durvalumab with serial biopsies.

Jiwon Koh, Seoul National University College of Medicine, Seoul, South Korea

PS12-02: CXCL11 in the tumor immune microenvironment modulates resistance to endocrine therapy in hormone receptor-positive breast cancer.

Fabiana Napolitano, UT Southwestern Medical Center, Dallas, Texas

PS12-03: Molecular characterization of the NeoPalAna Endocrine Resistant (ET-R) Cohort: implications for CDK4/6 inhibitor (CDK4/6i) and ET resistance mechanisms in primary estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC).

Tim Kong, Washington University School of Medicine, St. Louis, Missouri

PS12-04: HDAC抑制剂联合蒽环类药物引发MHC-II+ TNBC与CD69+CD4+Trm协同促进免疫治疗之间的相互作用

HDACi combined with anthracycline elicits interactions between MHC-II+ triple-negative breast cancer and CD69+CD4+Trm orchestrating synergistic immunotherapy.

王泽浩 复旦大学附属肿瘤医院

PS12-05: PARP7 inhibition combined with radiotherapy overcomes ICI resistance in breast cancer.

Lynn Lerner, University of North Carolina School of Medicine, Chapel Hill, North Carolina

PS12-06: An In Situ Tumor Vaccine Against Triple Negative Breast Cancer.

Nicole McCuen, UT Southwestern Medical Center, Dallas, Texas

PS12-07: DNA methyltransferase 3A (DNMT3A) protein expression in triple-negative breast cancer (TNBC): Impact on clinical outcomes, gene expression, and tumor microenvironment.

Roberto Leon-Ferre, Mayo Clinic, Rochester, Minnesota

PS12-08: Biological sex-linked immune modulation but not cross-sex estrogen therapy reduces the efficacy of PARP inhibition in the treatment of Brca1 breast tumors.

Jan Heng, Beth Israel Deaconess Medical Center, Boston, Massachusetts

PS12-09: Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk, early-stage triple-negative breast cancer: Overall survival and subgroup results from the phase 3 KEYNOTE-522 study.

Rebecca Dent, National Cancer Center Singapore, Singapore

• 7:30-7:45 Discussant (PS12-01, PS12-02, PS12-03, PS12-04)

免疫生物学1

Immunobiology 1

Giampaolo Bianchini, Vita-Salute San Raffaele University, Milan, Italy

• 7:45-8:00 Panel Q&A

• 8:00-8:15 Discussant (PS12-05, PS12-06, PS12-07, PS12-08, PS12-09)

免疫生物学2

Immunobiology 2

Antonio Giordano, Harvard University, Cambridge, Massachusetts

• 8:15-8:30 Panel Q&A

地点和时间： Stars at Night 1-2，12月13日 7:00 – 8:30 am 

主持人：Aditya Bardia, UCLA David Geffen School of Medicine, Los Angeles, California

PS13-01: Evaluation of breast cancer stem cell gene expression signatures in single-cell RNA sequencing (scRNAseq) data from the OPPORTUNE and FELINE trials, and the association with treatment resistance laparib-induced early dynamics of tumor immune microenvironment.

Peter Hall, Edinburgh Cancer Research Centre, Edinburgh, United Kingdom

PS13-03: Decoupling of oestrogen response and proliferation in post-menopausal ER+ HER2- primary breast cancer after 2-week aromatase inhibitor treatment in the POETIC trial.

Istvan Kleijn, The Institute of Cancer Research: Royal Cancer Hospital, London, United Kingdom

PS13-04: DREAM complex assembly and stable cell cycle control underlies long-term clinical response to CDK4/6 inhibition.

Rei Kudo, Memorial Sloan Kettering Cancer Center, New York, New York

PS13-05: The UNDERSTAND trial: a multi-omic platform for investigating CDK4/6 inhibitors resistance mechanisms in HR+ advanced breast cancer.

Andrea Vingiani, University of Milan, Milan, Italy

PS13-07: Enhancing T-DXd Efficacy in HER2-positive Breast Cancer Resistant to HER2 ADC by Non-biased Kinase-related Target Screening.

Jangsoon Lee, University of Hawai’i Cancer Center, Honolulu, Hawaii

PS13-08: ARID1A as a Novel Regulator of Trop2-ADC Efficacy in Trop2-Low Hormone Receptor–Positive Breast Cancer.

Nanae Ogata, University of Hawai’i at Manoa, Honolulu, Hawaii

PS13-09: Mechanisms of Resistance to Trastuzumab Deruxtecan in Breast Cancer Elucidated by Multi-omic Molecular Profiling.

George W. Sledge Jr., Stanford Women’s Cancer Center, Palo Alto, California

• 7:30-7:45 Discussant (PS13-01, PS13-03, PS13-04, PS13-05)

内分泌治疗

Endocrine Therapy

Amy Jo Chien, University of California San Francisco, San Francisco, California

• 7:45-8:00 Panel Q&A

• 8:00-8:15 Discussant (PS13-07, PS13-08, PS13-09)

化疗

Chemotherapy 

Barbara Pistilli, Gustave Roussy Cancer Center, Villejuif, France

• 8:15-8:30 Panel Q&A

地点和时间：Stars at Night 3-4，12月13日 7:00 – 8:30 am

主持人：William Gradishar, Northwestern University Feinberg School of Medicine, Chicago, Illinois

PS14-01: Rhenium (186Re) obisbemeda (rhenium nanoliposome,186RNL) for the treatment of leptomeningeal metastases (LM): Update on Phase 1 dose escalation study.

Andrew Brenner, UT Health Mays Cancer Center, San Antonio, Texas

PS14-02: 大分割立体定向放疗（FSRT）治疗1-10个乳腺癌脑转移的患者：一项前瞻性Ⅱ期试验A

Prospective Phase II Trial of Hypofractionated Stereotactic Radiotherapy (FSRT) for Patients with 1-10 Brain Metastases from Breast Cancer.

孟晋 复旦大学附属肿瘤医院

PS14-03: 脑渗透性口服选择性雌激素受体降解剂（SERD）SIM0270在ER阳性/HER2阴性晚期乳腺癌患者中的应用：一项Ⅰ期研究更新分析

Updated analyses from a Phase I study of the brain-penetrant oral SERD- SIM0270 in patients with ER-positive,HER2-negative advanced breast cancer.

张清媛 哈尔滨医科大学附属肿瘤医院

PS14-04: SIM0270，一种脑渗透性口服SERD，联合依维莫司在ER阳性/HER2阴性晚期乳腺癌患者中的Ⅰb期研究

SIM0270, a brain-penetrant oral SERD, in combination with everolimus in patients with ER+/HER2- advanced breast cancer: the phase Ib study.

张剑 复旦大学附属肿瘤医院

PS14-05: Clinically actionable genomic alterations in breast cancer brain metastases.

Gaia Griguolo, Veneto Institute of Oncology, Padua, Italy

PS14-06: Gene expression profiling of brain metastases and matched primary breast tumours with focus on the immune system and tumour microenvironment.

Anna Thulin, University of Gothenburg, Gothenburg, Sweden

PS14-07: Spatial transcriptomics of matched breast cancer brain metastases and primary tumors identifies a brain-specific immune-suppressive transcriptional program.

Patrick Kurnia, Dana-Farber Cancer Institute, Boston, Massachusetts

PS14-08: Targeting CXCL1-CXCR2 axis blocks brain metastasis in inflammatory breast cancer.

Xiaoding Hu, MD Anderson Cancer Center, Houston, Texas

PS14-09: Central Nervous System as the Primary Site of First Relapse in Patients with Triple-Negative Breast Cancer Achieving Pathological Complete Response After Neoadjuvant Treatment.

Davide Massa, Instituto Ongcologio Veneto IOV – IRCCS, Padua, Italy

PS14-10: Effects of trastuzumab deruxtecan (T-DXd) on health-related quality of life (HRQOL) & neurological function in patients (pts) w/ HER2+ advanced/metastatic breast cancer (mBC) with or without brain metastases (BM): DESTINY-Breast12(DB-12) results

Nadia Harbeck, Ludwig-Maximilians-Universitӓt München (LMU), Munich, Germany

• 7:30-7:45 Discussant (PS14-01, PS14-02, PS14-03, PS14-04, PS14-05)

临床护理主题

Topics in Clinical Care

Carey Anders, Duke University Cancer Center, Durham, North Carolina

• 7:45-8:00 Panel Q&A

• 8:00-8:15 Discussant (PS14-06, PS14-07, PS14-08, PS14-09, PS14-10)

转化治疗学主题

Topics in Translational Therapeutics

Andrew Brenner, UT Health Mays Cancer Center, San Antonio, Texas

• 8:15-8:30 Panel Q&A

地点和时间：Hall 1，12月13日 8:30 – 9:00 am 

主持人：Carlos Arteaga, UT Southwestern Medical Center, Dallas, Texas

细胞图谱在癌症免疫学中作为指南针的作用

Cell Atlases as Roadmaps in Cancer Immunology

Walid Khaled, University of Cambridge, Cambridge, United Kingdom

地点和时间：Hall 1，12月13日 9:00 – 11:45 am

主持人：Hikmat Abdel-Razeq, King Hussein Cancer Center, Amman, Jordan, and Reshma Jagsi, Emory University, Atlanta, Georgia

GS3-01: Circulating tumor DNA surveillance in ZEST, a randomized, phase 3, double-blind study of niraparib or placebo in patients w/ triple-negative breast cancer or HER2+ BRCA-mutated breast cancer with molecular residual disease after definitive therapy.

Nicholas Turner, Ralph Lauren Centre for Breast Cancer Research, London, United Kingdom

GS3-02: Discussant about GS3-01

Ian Krop, Yale School of Medicine, New Haven, Connecticut

GS3-03: Impact of Anthracyclines in High Genomic Risk Node-Negative HR+/HER2- Breast Cancer.

Nan Chen, University of Chicago Medicine, Chicago, Illinois

GS3-04: (Neo)adjuvant nab-PAC weekly vs sb-PAC q2w, followed by EC q2w, in genomically or clinically high-risk HR+/HER- early breast cancer according to ET-response: final survival results from the WSG ADAPT-HR+/HER2- chemotherapy-trial.

Sherko Kuemmel, German Medical Institute, Berlin, Germany

GS3-05: NSABP B-59/GBG-96-GeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo followed by adjuvant atezolizumab or placebo in patients with Stage II and III triple-negative breast cancer.

Charles Geyer, University of Pittsburgh, Pittsburgh, Pennsylvania

GS3-06: 新辅助卡瑞利珠单抗联合化疗治疗早期或局部晚期TNBC：一项随机、双盲、Ⅲ期试验

Neoadjuvant camrelizumab plus chemotherapy (chemo) for early or locally advanced triple-negative breast cancer (TNBC): a randomized, double-blind, phase 3 trial.

邵志敏 复旦大学附属肿瘤医院

GS3-07: Discussant about GS3-05 and 06

Giampaolo Bianchini, Vita-Salute San Raffaele University, Milano, Italy

GS3-08: In situ detection of individual classical MHC-I gene products in breast cancer identifies gene- and subtype-specific biased antigen presentation loss.

Paula Gonzalez-Ericsson, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee

GS3-09: Multimodal integration of real world clinical and genomic data for the prediction of CDK4/6 inhibitors outcomes in patients with HR+/HER2- metastatic breast cancer.

Pedram Razavi, Memorial Sloan Kettering Cancer Center, New York, New York

GS3-10: Paired DNA and RNA analysis of CALGB 40603 (Alliance) reveals insights into the molecular and prognostic landscape of stage II-III triple-negative breast cancer.

Brooke Felsheim, UNC School of Medicine, Chapel Hill, North Carolina

GS3-11: Discussant about GS3-09 and 3-10

Fred Howard, University of Chicago Medicine, Chicago, Illinois

地点和时间：Hall 1，12月13日 12:00– 12:55 pm

主持人：Peter Fasching, University Hospital Erlangen and Comprehensive Cancer Center Erlangen-EMN, Germany

RF3-01: TBCRC 056: A phase II study of neoadjuvant niraparib with dostarlimab for patients with BRCA- or PALB2-mutated breast cancer: Results from the ER+/HER2- cohort.

Erica Mayer, Dana-Farber Cancer Institute, Boston, Massachusetts

RF3-02: Efficacy of adjuvant avelumab by PD-L1, tumor infiltrating lymphocytes and residual cancer burden in high-risk triple negative breast cancer: secondary and exploratory endpoints of the phase III A-BRAVE trial.

Maria Vittoria Dieci, University of Padua, Padua, Italy

RF3-03: Nivolumab + Ipilimumab (NIVO+IPI) compared to capecitabine for triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy – Final results of BreastImmune-03, a multicenter randomized open-label phase II trial.

Olivier Trédan, Centre Lèon Bèrard, Lyon, France

RF3-04: NRG-BR004: A Randomized, Double-blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-line HER2-positive Metastatic Breast Cancer.

Vicente Valero, MD Anderson Cancer Center, Houston, Texas

RF3-05: A Phase 2 Study of Neoadjuvant HER2-targeted Therapy +/- Immunotherapy with Pembrolizumab (neoHIP).

Heather McArthur, UT Southwestern Medical Center, Dallas, Texas

RF3-06: Mepitel Film for the Reduction of Radiation Dermatitis in Post-mastectomy Radiation Therapy: Results from Alliance A221803: A Multicenter Phase III Randomized Clinical Trial

Kimberly Corbin, Mayo Clinic, Rochester, Minnesota

RF3-07: ROSCO:Response to Optimal Selection of neoadjuvant Chemotherapy in Operable breast cancer: A randomised phase III, stratified biomarker trial of neoadjuvant 5-Fluorouracil, Epirubicin & Cyclophosphamide vs Docetaxel & Cyclophosphamide chemotherapy.

Daniel Rea, University of Birmingham, Birmingham, United Kingdom

地点和时间：Halls 2-3，12月13日 12:30 – 2:00 pm

壁报专场5详细日程见链接https://rs-os-lyh-dt-publicread-file-bosmetadata-prod.liangyihui.net/boss-upload/Pk2oYdrR4WV1r_x1EKnesQ/UY8WhZMJ9g0hQOmb.pdf

地点和时间：Room 221ABC，12月13日 12:30 – 2:00 pm

主持人：David Rimm, Yale School of Medicine, New Haven, Connecticut

IHC在乳腺癌中的简史和ASCO CAP指南

A Brief History of IHC in Breast Cancer and ASCO CAP Guidelines

Kim Allison, Stanford University/Stanford Cancer Institute, Palo Alto, California

FDA对乳腺癌药物开发中IHC检测的展望

FDA Perspectives on IHC testing in breast cancer drug development

Reena Philip, FDA, Gaithersburg, Maryland

阅读IHC的准确性评价

Evaluation of the accuracy of Reading IHC

Giuseppe Viale, European Institute of Oncology, Milan, Italy

数字测量精度的评价

Evaluation of the Accuracy of Digital Measuring

Andrew Beck, Path AI, Boston, Massachusetts

地点和时间：Stars at Night 3-4，12月13日 12:30 – 1:45 pm

主持人：Gretchen Gierach, National Cancer Institute, Bethesda, Maryland

预防疫苗：我们现在在哪里，我们向何处去？

Prevention Vaccines: Where Are We Now and Where Are We Going?

Olivera Finn, University of Pittsburgh, Pittsburgh, Pennsylvania

我们可以使用生物标志物来实施预防吗？

Can We Use Biomarkers to Implement Prevention?

Seema Khan, Northwestern University Feinberg School of Medicine, Chicago, Illinois

从实验室到临床试验：乳腺癌预防的新靶点

From Bench to Clinical Trial: A New Target for Breast Cancer Prevention 

Geoff Lindeman, Walter and Eliza Hall Institute of Medical Research, Parkville, Australia

• Panel Discussion

地点和时间：Stars at Night 3-4，12月13日 2:00 – 2:50 pm

主持人：Andrew Tutt, The Institute of Cancer Research, London, United Kingdom

开场致辞和投票

Opening Remarks and Polling

支持方

Debate For

Allison Kurian, Stanford University, Palo Alto, California

反对方

Debate Against

Raymond Kim, UHN Princess Margaret Cancer Centre, Toronto, Canada

闭幕致辞和投票

Closing Remarks and Polling

地点和时间：Stars at Night 1-2，12月13日 3:00 – 5:00 pm

主持人：Carlos Arteaga, UT Southwestern Medical Center, Dallas, Texas; and Virginia Kaklamani, UT Health Mays Cancer Center, San Antonio, Texas

基础科学

Basic Science

Neil Vasan, Columbia University, New York, New York

转化科学最新进展

Translational Science Updates 

Pedram Razavi, Memorial Sloan Kettering Cancer Center, New York, New York

早期乳腺癌最新进展

Early Breast Cancer Updates

曾纪颖 中国香港大学

晚期乳腺癌最新进展

Advanced Breast Cancer Updates 

Michael Danso, Virginia Oncology Associates, Norfolk, Virginia

时间：12月13日 5:00 – 5:30 pm

地点和时间：Stars at Night 1-2，12月13日 5:30 – 7:00 pm

主持人：Joyce O’Shaughnessy, Baylor-Sammons Cancer Center, Dallas, Texas
Patient Advocate: Stacey Tinianov, Santa Cruz, California

肿瘤内科

Medical Oncology

Cristina Saura, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
Antonio Wolff, Johns Hopkins Medicine, Baltimore, Maryland

放射肿瘤学

Radiation Oncology

Atif Khan, Memorial Sloan Kettering Cancer Center, New York, New York

肿瘤外科

Surgical Oncology

Alastair Thompson, Baylor College of Medicine, Houston, Texas

本文整理自SABCS官网公布的信息，不代表名单为实际现场参会专家。若有任何遗漏或错误，可联系我们进行修改。